艾迪药业 (688488)
Jiangsu Aidea Pharmaceutical Group Co., Ltd.
K-Line Chart
No K-line data available
Company NameJiangsu Aidi Pharmaceutical Group Co., Ltd.
Listing Date2020-07-20
Issue Price13.99RMB
Registered Capital42078.280810k RMB
Legal RepresentativeFu Heliang
Registered AddressNo. 69, West Xinganquan Road, Hanjiang District, Yangzhou City, Jiangsu Province
IndustryBiological Products
Main BusinessPrimarily engaged in the production and sales of human-derived protein products, while also conducting some generic drug business and distributing Abbott's HIV diagnostic equipment and reagents. The company is currently laying out R&D for innovative drugs in the fields of anti-AIDS, anti-inflammatory, and anti-tumor therapies.
Company ProfileJiangsu Aidi Pharmaceutical Group Co., Ltd. was founded in 2009. It is a group company focused on the pharmaceutical field, integrating drug R&D, production, and sales. Its subsidiaries include Yangzhou Aidi Pharmaceutical Co., Ltd., Yangzhou Aidi Pharmaceutical Technology Co., Ltd., and Nanjing Ansel Pharmaceutical Technology Co., Ltd. The company has established drug R&D and production bases to support its future development and possesses a well-known domestic human-derived protein production base.
The company's management team has accumulated over twenty years of practical experience in the biopharmaceutical field and is committed to the R&D of innovative drugs. It has won the National Science and Technology Progress Second Prize and has successively developed National Class I and Class II new drugs. The company emphasizes talent recruitment, development, and cultivation, having successfully attracted high-tech talents such as experts from the 'Thousand Talents Plan' of the Organization Department of the CPC Central Committee and executives from multinational corporations. On its development path, the company will always adhere to the mission of 'Creating Quality Medicine with Sincerity and Integrity, Pursuing Excellence with Perfection and Virtue,' uphold the corporate culture of 'Integrity, Responsibility, Innovation, and Perseverance,' establish itself in the human-derived protein field, focus on building three major therapeutic areas (oncology, antiviral, and cardiovascular/cerebrovascular), and achieve a product portfolio layout driven by both 'Generic Drugs + Innovative Drugs'.
Stock Details
1. Key Indicators
- Total Shares(W): 42078.28
- Circulating A-Shares(W): 42078.28
- Earnings Per Share(RMB): -0.0200
- Net Assets Per Share(RMB): 2.3243
- Operating Revenue(W RMB): 55240.02
- Total Profit(W RMB): 2662.29
- **Net Profit Attributable to Parent(W RMB) **: -684.05
- Net Profit Growth Rate(%): 88.78
- Weighted Return on Equity(%): -0.7000
- Operating Cash Flow Per Share(RMB): 0.0650
- Undistributed Profit Per Share(RMB): -0.8116
- Capital Reserve Per Share(RMB): 2.1102
2. Main Business
The main business covers:
- Production and sales of human-derived protein products
- Generic drug business
- Distribution of Abbott's HIV diagnostic equipment and reagents
- Anti-HIV related products
3. Company Basic Information
- Company Name: Jiangsu Aidea Pharmaceutical Group Co., Ltd.
- Listing Date: 2020-07-20
- Industry: Pharmaceutical Manufacturing
- Address: No. 69 West Xinganquan Road, Hanjiang District, Yangzhou City, Jiangsu Province
- Website: https://www.aidea.com.cn/
- Company Profile: The company was established in 2019 through the overall transformation of Jiangsu Aidea Pharmaceutical Co., Ltd., focusing on drug research and development, production and sales. Its main businesses include human-derived protein products, generic drugs, and distribution of HIV diagnostic equipment and reagents.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Guangzhou Weimei Investment Co., Ltd. | Corporate Entity | 9450.00 | 22.46 |
| 2 | Weimei Investment (Hong Kong) Co., Ltd. | Corporate Entity | 7769.34 | 18.46 |
| 3 | AEGLE TECH LIMITED | Corporate Entity | 1620.00 | 3.85 |
| 4 | Invesco Great Wall Business Model优选混合型证券投资基金(LOF)A类 | Fund | 622.90 | 1.48 |
| 5 | Shanghai Tongxiao Investment Development Center (Limited Partnership)-Tongxiao Zhiyuan Changjing No.1 Private Securities Investment Fund | Private Securities Investment Fund | 573.08 | 1.36 |
| 6 | China Universal Healthcare Mixed Securities Investment Fund | Fund | 466.07 | 1.11 |
| 7 | Suzhou Guantianxia Investment Co., Ltd. | Corporate Entity | 450.00 | 1.07 |
| 8 | Penghua Pharmaceutical Technology Stock Securities Investment Fund A Class | Fund | 412.55 | 0.98 |
| 9 | Yongwin Pharmaceutical Health Stock Securities Investment Fund A Class | Fund | 115.73 | 0.28 |
| 10 | Hongtu Innovation Healthcare Stock Initiated Securities Investment Fund | Fund | 75.46 | 0.18 |
5. Concept Sectors
- Generic Drugs
- Innovative Drugs
- DeepSeek
- Margin Trading & Securities Lending
- Consecutive Losses
- Restructuring Stocks
- Specialized, Refined, Special and New Enterprises
- SSE Innovation
- Sci-Tech Innovation Growth
- Sci-Tech Innovation 200
Remarks
- Data update date: 2025-11-07
- Data source: Public Market Information